Bioglan AB is a contract development and manufacturing organization with over thirty years of experience in research, development, manufacturing, and marketing of pharmaceuticals. The company specializes in the development, production, and marketing of pharmaceuticals and medical devices, offering comprehensive support for pharmaceutical, healthcare, and life science companies across all stages of product development. With manufacturing authorization from the Swedish Medical Products Agency, Bioglan AB is capable of producing non-sterile semi-solid and liquid products at pilot scale for clinical trials or at full-scale for commercial markets, while also serving as a QP release site for other product types. The company's quality system complies with EU and FDA GMP (Good Manufacturing Practice) requirements as well as the ISO 13485 standard for Medical Devices.
Founded in 1984, Bioglan AB operates within the Health Care, Manufacturing, and Pharmaceutical industries. Despite the absence of specific headquarters or recent investment details, the company emphasizes its reliability, efficiency, and flexibility in delivering high-quality projects in a cost-effective manner, proudly meeting the global market's quality requirements.
There is no investment information
No recent news or press coverage available for Bioglan AB.
We care about your data, and we'd love to use cookies make your experience better.